Evidence map›Paper›PMID 36803380›Full record

ArticleSubstance abuse treatment, prevention, and policy2023

Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report.

Florence Jaguga, Philip Kirwa, Benson Gakinya, Imran Manji, Thomas Andale, Daniel Kinyanjui, Edith Kamaru Kwobah, Felicita Mwangi, Kituyi Werunga, Josephat Kerema and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Florence JagugaMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya. flokemboi@gmail.com.
Philip KirwaMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Benson GakinyaSchool of Medicine, Moi University College of Health Sciences, PO BOX 4606, Eldoret, Kenya.
Imran ManjiMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Thomas AndaleMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Daniel KinyanjuiSchool of Medicine, Moi University College of Health Sciences, PO BOX 4606, Eldoret, Kenya.
Edith Kamaru KwobahMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Felicita MwangiAlbury Wodonga Health, Kerferd Unit 37/45 corner Dixon and docker streets, Wangaratta, Victoria, 3677, Australia.
Kituyi WerungaSchool of Medicine, Moi University College of Health Sciences, PO BOX 4606, Eldoret, Kenya.
Josephat KeremaMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Charles KwobahSchool of Medicine, Moi University College of Health Sciences, PO BOX 4606, Eldoret, Kenya.
Eunice TemetMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Julia SongokSchool of Medicine, Moi University College of Health Sciences, PO BOX 4606, Eldoret, Kenya.
Wilson K AruasaMoi Teaching and Referral Hospital, PO BOX -30100, Eldoret, Kenya.
Moi University · KEAlbury Wodonga Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlcohol use disorder is prevalent globally and in Kenya, and is associated with significant health and socio-economic consequences. Despite this, available pharmacological treatment options are limited. Recent evidence indicates that intravenous (IV) ketamine can be beneficial for the treatment of alcohol use disorder, but is yet to be approved for this indication. Further, little has been done to describe the use of IV ketamine for alcohol use disorder in Africa. The goal of this paper, is to: 1) describe the steps we took to obtain approval and prepare for off-label use of IV ketamine for patients with alcohol use disorder at the second largest hospital in Kenya, and 2) describe the presentation and outcomes of the first patient who received IV ketamine for severe alcohol use disorder at the hospital. CASE PRESENTATION: In preparing for the off-label use of ketamine for alcohol use disorder, we brought together a multi-disciplinary team of clinicians including psychiatrists, pharmacists, ethicists, anesthetists, and members of the drug and therapeutics committee, to spearhead the process. The team developed a protocol for administering IV ketamine for alcohol use disorder that took into account ethical and safety issues. The national drug regulatory authority, the Pharmacy and Poison's Board, reviewed and approved the protocol. Our first patient was a 39-year-old African male with severe alcohol use disorder and comorbid tobacco use disorder and bipolar disorder. The patient had attended in-patient treatment for alcohol use disorder six times and each time had relapsed between one to four months after discharge. On two occasions, the patient had relapsed while on optimal doses of oral and implant naltrexone. The patient received IV ketamine infusion at a dose of 0.71 mg/kg. The patient relapsed within one week of receiving IV ketamine while on naltrexone, mood stabilizers, and nicotine replacement therapy. DISCUSSION &

conclusionsThis case report describes for the first time the use of IV ketamine for alcohol use disorder in Africa. Findings will be useful in informing future research and in guiding other clinicians interested in administering IV ketamine for patients with alcohol use disorder.

Indexed as

AlcoholismKetamineSmoking CessationAdultHospitalsHumansKenyaMaleNaltrexoneReferral and ConsultationTobacco Use Cessation DevicesKetamineNaltrexoneAlcohol use disorderCase reportKenyaKetamineOff-label

Identifiers

PMID36803380
PMCPMC9936629
OpenAlexW4321249426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.